Establishment of an optimized CTC detection model consisting of EpCAM, MUC1 and WT1 in epithelial ovarian cancer and its correlation with clinical characteristics.
OA: closed
CC-BY-4.0
Abstract
ObjectiveEmerging studies have demonstrated the promising clinical value of circulating tumor cells (CTCs) for diagnosis, disease assessment, treatment monitoring and prognosis in epithelial ovarian cancer. However, the clinical application of CTC remains restricted due to diverse detection techniques with variable sensitivity and specificity and a lack of common standards.MethodsWe enrolled 160 patients with epithelial ovarian cancer as the experimental group, and 90 patients including 50 patients with benign ovarian tumor and 40 healthy females as the control group. We enriched CTCs with immunomagnetic beads targeting two epithelial cell surface antigens (EpCAM and MUC1), and used multiple reverse transcription-polymerase chain reaction (RT-PCR) detecting three markers (EpCAM, MUC1 and WT1) for quantification. And then we used a binary logistic regression analysis and focused on EpCAM, MUC1 and WT1 to establish an optimized CTC detection model.ResultsThe sensitivity and specificity of the optimized model is 79.4% and 92.2%, respectively. The specificity of the CTC detection model is significantly higher than CA125 (92.2% vs. 82.2%, P=0.044), and the detection rate of CTCs was higher than the positive rate of CA125 (74.5% vs. 58.2%, P=0.069) in early-stage patients (stage I and II). The detection rate of CTCs was significantly higher in patients with ascitic volume ≥500 mL, suboptimal cytoreductive surgery and elevated serum CA125 level after 2 courses of chemotherapy (P<0.05). The detection rate of CTCEpCAM + and CTCMUC1+ was significantly higher in chemo-resistant patients (26.3% vs. 11.9%; 26.4% vs. 13.4%, P<0.05). The median progression-free survival time for CTCMUC1+ patients trended to be longer than CTCMUC1- patients, and overall survival was shorter in CTCMUC1+ patients (P=0.043).ConclusionsOur study presents an optimized detection model for CTCs, which consists of the expression levels of three markers (EpCAM, MUC1 and WT1). In comparison with CA125, our model has high specificity and demonstrates better diagnostic values, especially for early-stage ovarian cancer. Detection of CTCEpCAM+ and CTCMUC1+ had predictive value for chemotherapy resistance, and the detection of CTCMUC1+ suggested poor prognosis.
Full text
15,992 characters
· extracted from
oa-html
· click to expand
[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30. doi: 10.3322/caac.21590 [PubMed]
[2]
Stewart C, Ralyea C, Lockwood S. Ovarian cancer: An integrated review. Semin Oncol Nurs 2019;35:151-6. doi: 10.1016/j.soncn.2019.02.001 [PubMed]
[3]
Sölétormos G, Duffy MJ, Othman AHS, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: Updated guidelines from the European group on tumor markers. Int J Gynecol Cancer 2016;26:43-51. doi: 10.1097/IGC.0000000000000586 [PubMed]
[4]
Stabile G, Zinicola G, Romano F, et al. Pelvic mass, ascites, hydrothorax: a malignant or benign condition. Meigs syndrome with high levels of CA 125. Prz Menopauzalny 2021;20:103-7. doi: 10.5114/pm.2021.106100 [PubMed]
[5]
de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-9. doi: 10.1158/1078-0432.CCR-08-0872 [PubMed]
[6]
Li S, Jiang J, Breast Disease Center, Southwest Hospital, Third Military Medical University. Progress in biological characteristics of circulating breast-tumor cells. Zhonghua Zhong Liu Fang Zhi Za Zhi (in Chinese) 2012;16:1272-5. doi: 10.16073/j.cnki.cjcpt.2012.16.004
[7]
Antonarakis ES, Lu C, Luber B, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol 2017;35:2149-56. doi: 10.1200/JCO.2016.70.1961 [PubMed]
[8]
Lorente D, Olmos D, Mateo J, et al. Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer. Eur Urol 2016;70:985-92. doi: 10.1016/j.eururo.2016.05.023 [PubMed]
[9]
Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-21. doi: 10.1200/JCO.2007.15.8923 [PubMed]
[10]
Heller G, McCormack R, Kheoh T, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: A comparison with prostate-specific antigen across five randomized phase III clinical trials. J Clin Oncol 2018;36:572-80. doi: 10.1200/JCO.2017.75.2998 [PubMed]
[11]
Huang X, Gao P, Song Y, et al. Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer. BMC Cancer 2015;15:202. doi: 10.1186/s12885-015-1218-9 [PubMed]
[12]
Zhang X, Li H, Yu X, et al. Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker. Cell Physiol Biochem 2018;48:1983-94. doi: 10.1159/000492521 [PubMed]
[13]
Wang T, Yao Y, Li Y, et al. Research progress of circulating tumor cells in ovarian epithelial carcinoma. Zhongguo Fu Chan Ke Lin Chuang Za Zhi (in Chinese) 2019;20:280-2.
[14]
Marth C, Kisic J, Kaern J, et al. Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer 2002;94:707-12. doi: 10.1002/cncr.10250 [PubMed]
[15]
Judson PL, Geller MA, Bliss RL, et al. Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol Oncol 2003;91:389-94. doi: 10.1016/j.ygyno.2003.08.004 [PubMed]
[16]
Liu JF, Kindelberger D, Doyle C, et al. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol 2013;131:352-6. doi: 10.1016/j.ygyno.2013.08.006 [PubMed]
[17]
Ning N, Zhan T, Zhang Y, et al. Improvement of specific detection of circulating tumor cells using combined CD45 staining and fluorescence in situ hybridization. Clin Chim Acta 2014;433:69-75. doi: 10.1016/j.cca.2014.02.019 [PubMed]
[18]
Pearl ML, Dong H, Tulley S, et al. Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs). Gynecol Oncol 2015;137:229-38. doi: 10.1016/j.ygyno.2015.03.002 [PubMed]
[19]
Guo YX, Neoh KH, Chang XH, et al. Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer. Oncotarget 2018;9:7522-33. doi: 10.18632/oncotarget.23943 [PubMed]
[20]
Kim M, Suh DH, Choi JY, et al. Post-debulking circulating tumor cell as a poor prognostic marker in advanced stage ovarian cancer: A prospective observational study. Medicine (Baltimore) 2019;98:e15354. doi: 10.1097/MD.0000000000015354 [PubMed]
[21]
Banys-Paluchowski M, Fehm T, Neubauer H, et al. Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer. Arch Gynecol Obstet 2020;301:1027-35. doi: 10.1007/s00404-020-05477-7 [PubMed]
[22]
Cheng H, Wang S, Luan W, et al. Combined detection and subclass characteristics analysis of CTCs and CTECs by SE-iFISH in ovarian cancer. Chin J Cancer Res 2021;33:256-70. doi: 10.21147/j.issn.1000-9604.2021.02.12 [PubMed]
[23]
Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19:77-102. [PubMed]
[24]
Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1. 1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011;21:419-23. doi: 10.1097/IGC.0b013e3182070f17 [PubMed]
[25]
Nie L, Li F, Huang X, et al. Folic acid targeting for efficient isolation and detection of ovarian cancer CTCs from human whole blood based on two-step binding strategy. ACS Appl Mater Interfaces 2018;10:14055-62. doi: 10.1021/acsami.8b02583 [PubMed]
[26]
Fan T, Zhao Q, Chen JJ, et al. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol 2009;112:185-91. doi: 10.1016/j.ygyno.2008.09.021 [PubMed]
[27]
Aktas B, Kasimir-Bauer S, Heubner M, et al. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy. Int J Gynecol Cancer 2011;21:822-30. doi: 10.1097/IGC.0b013e318216cb91 [PubMed]
[28]
Sang M, Wu X, Fan X, et al. Multiple MAGE-A genes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer. Biomarkers 2014;19:34-42. doi: 10.3109/1354750X.2013.865275 [PubMed]
[29]
Pearl ML, Zhao Q, Yang J, et al. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer. Gynecol Oncol 2014;134:581-90. doi: 10.1016/j.ygyno.2014.06.013 [PubMed]
[30]
Kuhlmann JD, Wimberger P, Bankfalvi A, et al. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem 2014;60:1282-9. doi: 10.1373/clinchem.2014.224808 [PubMed]
[31]
Blassl C, Kuhlmann JD, Webers A, et al. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel. Mol Oncol 2016;10:1030-42. doi: 10.1016/j.molonc.2016.04.002 [PubMed]
[32]
Kolostova K, Pinkas M, Jakabova A, et al. Molecular characterization of circulating tumor cells in ovarian cancer. Am J Cancer Res 2016;6:973-80. [PubMed]
[33]
Liu Z, Guo W, Zhang D, et al. Circulating tumor cell detection in hepatocellular carcinoma based on karyoplasmic ratios using imaging flow cytometry. Sci Rep 2016;6:39808. doi: 10.1038/srep39808 [PubMed]
[34]
Chebouti I, Kasimir-Bauer S, Buderath P, et al. EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy. Oncotarget 2017;8:48820-31. doi: 10.18632/oncotarget.16179 [PubMed]
[35]
Suh DH, Kim M, Choi JY, et al. Circulating tumor cells in the differential diagnosis of adnexal masses. Oncotarget 2017;8:77195-206. doi: 10.18632/oncotarget.20428 [PubMed]
[36]
Lee M, Kim EJ, Cho Y, et al. Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer. Gynecol Oncol 2017;145:361-5. doi: 10.1016/j.ygyno.2017.02.042 [PubMed]
[37]
Rao Q, Zhang Q, Zheng C, et al. Detection of circulating tumour cells in patients with epithelial ovarian cancer by a microfluidic system. Int J Clin Exp Pathol 2017;10:9599-606. [PubMed]
[38]
Obermayr E, Bednarz-Knoll N, Orsetti B, et al. Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer. a study of the OVCAD consortium. Oncotarget 2017;8:106415-28. doi: 10.18632/oncotarget.22468 [PubMed]
[39]
Obermayr E, Maritschnegg E, Agreiter C, et al. Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells. Oncotarget 2017;9:812-23. doi: 10.18632/oncotarget.22549 [PubMed]
[40]
Po JW, Roohullah A, Lynch D, et al. Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. J Circ Biomark 2018;7: 1849454418782617. doi: 10.1177/1849454418782617 [PubMed]
[41]
Li N, Zuo H, Chen L, et al. Circulating tumor cell detection in epithelial ovarian cancer using dual-component antibodies targeting EpCAM and FRα. Cancer Manag Res 2019;11:10939-48. doi: 10.2147/CMAR.S211455 [PubMed]
[42]
Abreu M, Cabezas-Sainz P, Alonso-Alconada L, et al. Circulating tumor cells characterization revealed TIMP1 as a potential therapeutic target in ovarian cancer. Cells 2020;9:1218. doi: 10.3390/cells9051218 [PubMed]
[43]
Andree KC, van Dalum G, Terstappen LW. Challenges in circulating tumor cell detection by the CellSearch system. Mol Oncol 2016;10:395-407. doi: 10.1016/j.molonc.2015.12.002 [PubMed]
[44]
Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007;96:417-23. doi: 10.1038/sj.bjc.6603494 [PubMed]
[45]
Le Du F, Fujii T, Kida K, et al. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy. PLoS One 2020;15:e0229903. doi: 10.1371/journal.pone.0229903 [PubMed]
[46]
Zhou W, Ye C, Li L, et al. Adipocyte-derived SFRP5 inhibits breast cancer cells migration and invasion through Wnt and epithelial-mesenchymal transition signaling pathways. Chin J Cancer Res 2020;32:347-60. doi: 10.21147/j.issn.1000-9604.2020.03.06 [PubMed]
[47]
Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68. doi: 10.1038/nrc2499 [PubMed]
[48]
Tavsan Z, Ayar K H. EpCAM-claudin-tetraspanin-modulated ovarian cancer progression and drug resistance. Cell Adh Migr 2020;14:57-68. doi: 10.1080/19336918.2020.1732761 [PubMed]
[49]
Hou R, Jiang L, Liu D, et al. Lewis(y) antigen promotes the progression of epithelial ovarian cancer by stimulating MUC1 expression. Int J Mol Med 2017;40:293-302. doi: 10.3892/ijmm.2017.3009 [PubMed]
[50]
Liu Z, Yamanouchi K, Ohtao T, et al. High levels of Wilms’ tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer. Anticancer Res 2014;34:2331-40. [PubMed]
[51]
Jing Y, Zhou L, Chen J, et al. Quantitatively mapping the assembly pattern of epcam on cell membranes with peptide probes. Anal Chem 2020;92:1865-73. doi: 10.1021/acs.analchem.9b03901 [PubMed]
[52]
Zhao L, Li Y, Zhang Z, et al. Meta-analysis based gene expression profiling reveals functional genes in ovarian cancer. Biosci Rep 2020;40:BSR20202911. doi: 10.1042/BSR20202911 [PubMed]
[53]
Bellone S, Siegel ER, Cocco E, et al. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer 2009;19:860-6. doi: 10.1111/IGC.0b013e3181a8331f [PubMed]
[54]
Williams KA, Terry KL, Tworoger SS, et al. Polymorphisms of MUC16 (CA125) and MUC1 (CA15. 3) in relation to ovarian cancer risk and survival. PLoS One 2014;9:e88334. doi: 10.1371/journal.pone.0088334 [PubMed]
[55]
Schroeder JA, Masri AA, Adriance MC, et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004;23:5739-47. doi: 10.1038/sj.onc.1207713 [PubMed]
[56]
Feng H, Ghazizadeh M, Konishi H, et al. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol 2002;32:525-9. doi: 10.1093/jjco/hyf111 [PubMed]
[57]
Tashiro Y, Yonezawa S, Kim YS, et al. Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum Pathol 1994;25:364-72. doi: 10.1016/0046-8177(94)90144-9 [PubMed]
[58]
Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323-37. doi: 10.1158/1078-0432.CCR-09-0737 [PubMed]
[59]
Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, et al. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMC Cancer 2006;6:90. doi: 10.1186/1471-2407-6-90 [PubMed]
[60]
Qi XW, Zhang F, Wu H, et al. Wilms’ tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep 2015;5:8924. doi: 10.1038/srep08924 [PubMed]
[61]
Morales-Vásquez F, Pedernera E, Reynaga-Obregón J, et al. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. J Ovarian Res 2016;9:41. doi: 10.1186/s13048-016-0247-6 [PubMed]
[62]
Zhang M, Cheng S, Jin Y, et al. Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer 2021;1875:188503. doi: 10.1016/j.bbcan.2021.188503 [PubMed]
[63]
Wimberger P, Heubner M, Otterbach F, et al. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. Gynecol Oncol 2007;107:331-8. doi: 10.1016/j.ygyno.2007.07.073 [PubMed]
[64]
Molnar B, Sipos F, Galamb O, et al. Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients. Dig Dis 2003;21:320-5. doi: 10.1159/000075355 [PubMed]
[65]
Gasparri ML, Savone D, Besharat RA, et al. Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer. Tumour Biol 2016;37:71-5. doi: 10.1007/s13277-015-4299-9 [PubMed]
[66]
Lou E, Vogel RI, Teoh D, et al. Assessment of circulating tumor cells as a predictive biomarker of histology in women with suspected ovarian cancer. Lab Med 2018;49:134-9. doi: 10.1093/labmed/lmx084 [PubMed]
[67]
Zhou Y, Bian B, Yuan X, et al. Prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis. PLoS One 2015;10:e0130873. doi: 10.1371/journal.pone.0130873 [PubMed]
[68]
Zeng L, Liang X, Liu Q, et al. The predictive value of circulating tumor cells in ovarian cancer: A meta analysis. Int J Gynecol Cancer 2017;27:1109-17. doi: 10.1097/IGC.0000000000000459 [PubMed]
[69]
Cui L, Kwong J, Wang CC. Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis. J Ovarian Res 2015;8:38. doi: 10.1186/s13048-015-0168-9 [PubMed]
[70]
Poveda A, Kaye SB, McCormack R, et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol 2011;122:567-72. doi: 10.1016/j.ygyno.2011.05.028 [PubMed]
[71]
Chen H, Su Z, Li R, et al. Single-cell DNA methylome analysis of circulating tumor cells. Chin J Cancer Res 2021;33:391-404. doi: 10.21147/j.issn.1000-9604.2021.03.10 [PubMed]
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Ask this paper
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-08-10T06:11:17.106188+00:00
- unpaywall
- last seen: 2026-05-23T02:00:01.238055+00:00
License: CC-BY-4.0